113 related articles for article (PubMed ID: 7759734)
1. Fluosol in myocardial reperfusion injury.
Murray JJ; Vitola JV; Schaer GL; Forman MB
J Am Coll Cardiol; 1995 Jun; 25(7):1742-3. PubMed ID: 7759734
[No Abstract] [Full Text] [Related]
2. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes.
Kolodgie FD; Farb A; Carlson GC; Wilson PS; Virmani R
J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204
[TBL] [Abstract][Full Text] [Related]
3. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion.
Forman MB; Pitarys CJ; Vildibill HD; Lambert TL; Ingram DA; Virmani R; Murray JJ
J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335
[TBL] [Abstract][Full Text] [Related]
5. Limitation of no reflow injury by blood-free reperfusion with oxygenated perfluorochemical (Fluosol-DA 20%).
Kolodgie FD; Virmani R; Farb A
J Am Coll Cardiol; 1991 Jul; 18(1):215-23. PubMed ID: 2050924
[TBL] [Abstract][Full Text] [Related]
6. Role of perfluorochemical emulsions in the treatment of myocardial reperfusion injury.
Forman MB; Ingram DA; Murray JJ
Am Heart J; 1992 Nov; 124(5):1347-57. PubMed ID: 1442506
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and therapy of myocardial reperfusion injury.
Forman MB; Virmani R; Puett DW
Circulation; 1990 Mar; 81(3 Suppl):IV69-78. PubMed ID: 2407376
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of myocardial reperfusion injury in humans: results of a pilot study utilizing acute coronary angioplasty with perfluorochemical in anterior myocardial infarction.
Forman MB; Perry JM; Wilson BH; Verani MS; Kaplan PR; Shawl FA; Friesinger GC
J Am Coll Cardiol; 1991 Oct; 18(4):911-8. PubMed ID: 1894864
[TBL] [Abstract][Full Text] [Related]
9. Effect of hemodilution with dextran, stroma-free hemoglobin solution and fluosol-DA on experimental myocardial ischemia in the dog.
Biro GP
Bibl Haematol; 1981; (47):54-69. PubMed ID: 6175307
[No Abstract] [Full Text] [Related]
10. Myocardial reperfusion injury. Histopathological effects of perfluorochemical.
Virmani R; Forman MB; Kolodgie FD
Circulation; 1990 Mar; 81(3 Suppl):IV57-68. PubMed ID: 2407375
[TBL] [Abstract][Full Text] [Related]
11. Extended use of Fluosol emulsion in acute myocardial ischemia treatment.
Ohyanagi H; Saitoh Y; Uchida T; Watanabe M; Yamanouchi K; Yokoyama K; Mitsuno T
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):941-9. PubMed ID: 1391538
[TBL] [Abstract][Full Text] [Related]
12. Protection against ischemia during prolonged balloon inflation by distal coronary perfusion with use of an autoperfusion catheter or Fluosol.
Robalino BD; Marwick T; Lafont A; Vaska K; Whitlow PL
J Am Coll Cardiol; 1992 Nov; 20(6):1378-84. PubMed ID: 1430688
[TBL] [Abstract][Full Text] [Related]
13. Phagocytic activation of human neutrophils by the detergent component of fluosol.
Ingram DA; Forman MB; Murray JJ
Am J Pathol; 1992 May; 140(5):1081-7. PubMed ID: 1316083
[TBL] [Abstract][Full Text] [Related]
14. [An emulsion of fluorocarbons as a protective agent against myocardial ischemia].
Islamov BI; Ladilov IuV; Buevich VA; Bobrovskiĭ RV
Vestn Akad Med Nauk SSSR; 1991; (3):39-43. PubMed ID: 1882539
[TBL] [Abstract][Full Text] [Related]
15. Reduction in reperfusion injury by blood-free reperfusion after experimental myocardial infarction.
Schaer GL; Karas SP; Santoian EC; Gold C; Visner MS; Virmani R
J Am Coll Cardiol; 1990 May; 15(6):1385-93. PubMed ID: 2329241
[TBL] [Abstract][Full Text] [Related]
16. Medical oxygen transport using perfluorochemicals.
Kaufman RJ
Biotechnology; 1991; 19():127-62. PubMed ID: 1786469
[No Abstract] [Full Text] [Related]
17. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty.
Kerins DM
Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713
[No Abstract] [Full Text] [Related]
18. Beneficial effect of fluorocarbon reperfusion on postoperative cardiac dysfunction of transplanted heart.
Ueda K; Genda T; Hirata I; Shimada M; Shibata T; Ueda T; Omoto R
J Heart Lung Transplant; 1992; 11(4 Pt 1):646-55. PubMed ID: 1498127
[TBL] [Abstract][Full Text] [Related]
19. Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol.
Kent KM; Cleman MW; Cowley MJ; Forman MB; Jaffe CC; Kaplan M; King SB; Krucoff MW; Lassar T; McAuley B
Am J Cardiol; 1990 Aug; 66(3):279-84. PubMed ID: 2195864
[TBL] [Abstract][Full Text] [Related]
20. Fluosol and experimental spinal cord ischemia.
Kolluri S; DeGirolami U; Heros R; Vacanti F; Zervas N
Acta Neuropathol; 1988; 75(5):491-4. PubMed ID: 2454012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
